TB-500 + CJC-1295 Stack: Evidence, Mechanism Overlap, and Protocol

What Are TB-500 and CJC-1295, and Why Combine Them?

TB-500 and CJC-1295 address different biological bottlenecks in tissue repair. TB-500 provides the cell-migration and anti-inflammatory signaling driven by thymosin beta-4, while CJC-1295 raises circulating GH and IGF-1 to accelerate protein synthesis and collagen remodeling. Stacking them is an attempt to cover both the upstream anabolic signal and the local cellular repair machinery simultaneously.

TB-500: The Thymosin Beta-4 Fragment

Thymosin beta-4 (Tβ4) is a 43-amino-acid, ubiquitously expressed protein first isolated from bovine thymus in 1966. Its primary biochemical role is sequestering G-actin monomers, thereby regulating actin polymerization and cytoskeletal dynamics. [1] The active fragment most associated with repair signaling is the tetrapeptide Ac-SDKP, which is released from Tβ4 by prolyl oligopeptidase. TB-500 is a synthetic peptide engineered to mimic this region.

Animal studies show strong effects. In a murine full-thickness skin wound model, topical and systemic Tβ4 accelerated wound closure by 42% compared with vehicle control, with histology showing increased keratinocyte migration and neovascularization. [2] Cardiac studies in rats with ligated coronary arteries found that Tβ4 reduced infarct size and promoted cardiomyocyte survival, partly through activation of the integrin-linked kinase (ILK) pathway. [3]

CJC-1295: The Long-Acting GHRH Analogue

CJC-1295 is a 29-amino-acid analogue of growth hormone releasing hormone (GHRH) with a lysine residue modified to carry a maleimidopropionic acid drug affinity complex (DAC). The DAC binds reversibly to serum albumin, extending the terminal half-life from roughly 7 minutes (native GHRH) to approximately 6-8 days. [4]

Two phase-1 dose-escalation trials in healthy adults have been published. In the primary study (N=21 and N=22 in two cohorts), subcutaneous doses from 30 mcg/kg to 120 mcg/kg produced sustained, dose-dependent increases in mean plasma GH. At 60 mcg/kg, mean GH area under the curve rose approximately 2- to 3-fold above baseline and remained elevated for at least 14 days after a single injection. IGF-1 levels increased 1.5- to 1.7-fold and were maintained for up to 28 days post-dose. [4]

This is a meaningful distinction from GHRP compounds: CJC-1295 does not displace native pulsatility. It amplifies GH pulse amplitude while preserving the endogenous somatostatin feedback cycle, which is why it is sometimes preferred over continuous GH infusion in research contexts. [5]

Mechanism Overlap: Where the Two Pathways Converge

The mechanistic logic of this stack rests on at least three converging biology points: collagen synthesis, angiogenesis, and satellite cell activation. Each pathway is supported by either the Tβ4 literature or the GH/IGF-1 literature, but rarely by studies examining both together.

Collagen Synthesis and Extracellular Matrix Remodeling

IGF-1, elevated downstream of CJC-1295 administration, stimulates type-I and type-III collagen production in fibroblasts through the IGF-1 receptor/PI3K/Akt axis. [6] Tβ4 has been shown independently to upregulate matrix metalloproteinase-2 (MMP-2), which remodels the provisional fibrin matrix into organized collagen. [2] The two signals may therefore act at different phases of the same repair cascade: IGF-1 drives new collagen deposition, while Tβ4-related MMP-2 activity reorganizes the matrix architecture.

Angiogenesis

Both compounds promote blood vessel growth, but through different receptors. Tβ4 upregulates vascular endothelial growth factor (VEGF) and fibroblast growth factor-4 (FGF-4) in endothelial progenitor cells. [3] GH/IGF-1 signaling also increases VEGF expression, primarily through the JAK2-STAT5 pathway in vascular smooth muscle. [6] Whether combined administration produces additive or simply redundant angiogenic signaling has not been tested in any published study.

Satellite Cell Activation and Muscle Repair

Muscle satellite cells (skeletal muscle stem cells) respond to both IGF-1 and Tβ4. IGF-1 promotes satellite cell proliferation and differentiation through the MyoD and myogenin transcription factors. [7] Tβ4 appears to activate satellite cells through a separate route involving Wnt4 signaling, as demonstrated in a 2012 study in which Tβ4 pre-conditioning in mice increased the number of activated Pax7-positive satellite cells in injured tibialis anterior muscle. [8] A stack providing both signals could, in theory, expand the satellite cell pool (Tβ4) while simultaneously pushing those cells toward differentiation and hypertrophy (IGF-1). This remains mechanistic inference. No study has examined the combination.

Evidence Grade: An Honest Accounting

The evidence base for this stack is substantially asymmetric. CJC-1295 has peer-reviewed phase-1 human data. TB-500 does not.

What the CJC-1295 Human Data Actually Show

The Ionescu et al. (2008) trial published in the Journal of Clinical Endocrinology and Metabolism enrolled healthy adults aged 21-61 years. A single subcutaneous injection of CJC-1295 produced GH increases that persisted for 6 days at the 30 mcg/kg dose and for up to 14 days at 120 mcg/kg. IGF-1 remained elevated above baseline for up to 28 days. [4] Adverse events included transient flushing, nausea at higher doses, and water retention. No serious adverse events were reported in the short follow-up window.

What this trial does not tell us: long-term safety beyond 28 days, effects in people with metabolic dysfunction, or any outcomes related to tissue repair or athletic performance. The trial was a pharmacokinetic and safety study, not a functional outcomes study.

What the TB-500 Evidence Actually Consists Of

Published TB-500 evidence is entirely preclinical as of mid-2025. The major domains are:

• Wound healing (murine models): accelerated closure, keratinocyte migration, neovascularization. [2]
• Cardiac repair (rat ligation models): reduced infarct size, ILK activation. [3]
• Neurological recovery (rodent stroke models): reduced infarct volume and improved motor scores with Tβ4 administration in the first 24 hours post-ischemia. [9]
• Anti-inflammatory effects (in vitro): Tβ4 and Ac-SDKP reduce NF-kB activation and decrease TNF-alpha and IL-6 secretion in macrophage cell lines. [10]

No peer-reviewed phase-1 human trial for TB-500 or its parent peptide Tβ4 in a repair or recovery context has been published in a source on the HealthRX citation allow-list. Practitioner-reported outcomes from clinical settings and patient forums describe reduced injury recovery times and improved joint comfort, but these are anecdotal and subject to substantial confounding from concurrent interventions.

The table below summarizes the evidence grade for each compound by outcome domain, using the Oxford Centre for Evidence-Based Medicine (OCEBM) levels.

| Outcome Domain | TB-500 Highest Evidence Level | CJC-1295 Highest Evidence Level | |---|---|---| | GH/IGF-1 elevation | N/A (not a GH secretagogue) | Level 1b (phase-1 RCT in humans) [4] | | Wound healing | Level 5 (animal study) [2] | Level 5 (indirect via IGF-1) | | Muscle repair | Level 5 (animal study) [8] | Level 5 (mechanistic inference) | | Cardiac repair | Level 5 (animal study) [3] | No evidence | | Anti-inflammation | Level 6 (in vitro) [10] | No evidence | | Long-term safety (humans) | No evidence | No evidence |

Regulatory Status and Legal Considerations

Neither TB-500 nor CJC-1295 holds FDA approval for any human indication. The FDA's position on peptides for human use is explicit: compounded peptides not on the 503A or 503B approved lists cannot legally be dispensed to patients by compounding pharmacies in the United States. [11]

CJC-1295 was added to the FDA's list of drug substances that present demonstrable difficulties for compounding in 2024, effectively barring its compounding and prescribing by licensed pharmacies in the US. TB-500 (as a Tβ4 fragment) has not received an approved new drug application (NDA) and is not listed as a bulk drug substance eligible for compounding. [11]

Both compounds are sold as "research chemicals" by third-party vendors. Products sold under this label are not subject to pharmaceutical-grade manufacturing standards, sterility testing, or potency verification. The identity, purity, and concentration of compounds purchased from research chemical vendors cannot be assumed without independent third-party testing. This is a concrete safety risk, not a theoretical one.

Pharmacokinetics: How the Two Compounds Interact in Practice

TB-500, when injected subcutaneously, distributes rapidly to tissues. Tβ4 in animal studies shows peak tissue concentrations within 1-2 hours and a plasma half-life of approximately 30-70 minutes for the native peptide. The synthetic fragment TB-500 lacks published human pharmacokinetic data, but practitioners typically dose it two to three times weekly to maintain estimated tissue exposure.

CJC-1295 with DAC, by contrast, has a half-life of 6-8 days, meaning once-weekly or even once-every-two-weeks dosing produces sustained GH pulse amplification. [4]

There is no pharmacokinetic interaction study for the combination. The two peptides bind entirely different receptors (GHRH-R for CJC-1295 versus actin and putative surface receptors for Tβ4), so direct receptor competition is not expected. The more relevant interaction question is whether GH-induced insulin resistance from CJC-1295 might impair the repair environment in which TB-500 is expected to operate. GH is known to promote lipolysis and reduce peripheral insulin sensitivity, effects mediated through GH receptor signaling in adipose and muscle tissue. [12] Chronically elevated GH can raise fasting glucose by 10-20% in normal subjects. [12] Whether this metabolic shift blunts the anti-inflammatory benefit of Tβ4 in inflamed tissue is unknown.

Practitioner Protocols: What Is Actually Used

No published clinical protocol exists for the combination. The following reflects practitioner-reported approaches aggregated from compounding-pharmacy consultation notes and peer-reviewed gray literature on GHRH peptide use. Doses should be read as descriptive, not prescriptive.

Common Loading and Maintenance Structure

Practitioners who use this stack typically structure it as an 8-12 week course with a 4-6 week off period. The rationale for cycling is avoidance of GH receptor desensitization and preservation of endogenous GHRH pulsatility. No human data confirm that these off-periods are necessary at the doses used.

• CJC-1295 with DAC: 2 mg subcutaneous injection once weekly. Dose range reported in practice is 1-2 mg per week.
• TB-500: 2-2.5 mg subcutaneous injection twice weekly for the first 4 weeks (loading phase), then 2-2.5 mg once weekly for maintenance.

Injection Timing

CJC-1295 is typically injected in the evening to align with the normal nocturnal GH surge. TB-500 timing is considered less critical given that its proposed mechanism is local and systemic cell-migration signaling rather than neuroendocrine pulsatility.

Ipamorelin as a Common Third Agent

Many practitioners who use CJC-1295 add ipamorelin (a selective GHRP) to provide a GH-releasing peptide (GHRP) signal on top of the GHRH signal from CJC-1295. The CJC-1295 plus ipamorelin combination has more practitioner literature than the CJC-1295 plus TB-500 combination. The GHRH and GHRP axes are synergistic, with co-administration producing GH pulses roughly 3-fold larger than either agent alone in animal studies. [5] Adding TB-500 to a CJC-1295/ipamorelin base is described by some practitioners as a "triple stack" targeting anabolic signaling, GH secretion, and tissue repair simultaneously.

Side Effects and Monitoring Considerations

Known Side Effects From Published Data

For CJC-1295: flushing (occurs within 30-120 minutes of injection), water retention (dose-dependent), mild nausea at doses above 60 mcg/kg, and potential elevation in fasting glucose. [4] Long-term GH elevation carries theoretical risk of acromegalic changes, but no such cases have been documented at the doses described in phase-1 trials.

For TB-500: data are almost entirely from animal studies. Reported effects in preclinical work include transient hypotension at high doses and, at very high doses in rodents, potential pro-fibrotic effects in cardiac tissue paradoxically. [3] Practitioner-reported human side effects include injection-site reactions, mild fatigue in the first 1-2 weeks, and occasional flushing.

Monitoring Parameters a Physician Might Track

A prescribing physician monitoring a patient on this stack would reasonably check:

• IGF-1 (serum): to confirm GH axis activation and detect supraphysiologic levels. Target is typically mid-normal range for the patient's age and sex.
• Fasting glucose and insulin: given GH-mediated insulin resistance with CJC-1295.
• Blood pressure: given TB-500's vasodilatory potential at higher doses.
• CBC and CMP: as a baseline safety screen for any peptide protocol.

IGF-1 reference ranges for adults 30-50 years old run approximately 115-355 ng/mL by most laboratory assays. [13] Levels persistently above 400 ng/mL on a GH secretagogue protocol warrant dose reduction or discontinuation.

Who Should Not Use This Stack

The following represent groups in whom this combination is particularly ill-advised based on known pharmacology:

• Active or prior malignancy: IGF-1 is a known mitogen. Elevated circulating IGF-1 has been associated with increased risk of colorectal, prostate, and breast cancer in prospective cohort data, with relative risks in the range of 1.4-2.1 across studies. [14] This is not a clinical trial in the stack itself, but the biological plausibility is strong enough that oncology guidelines consistently advise against exogenous GH or GH-secretagogue use in cancer survivors. [15]
• Type 2 diabetes or pre-diabetes: GH-mediated insulin resistance from CJC-1295 could worsen glycemic control.
• Pregnancy or breastfeeding: no safety data exist; both peptides should be avoided.
• Age <21 years: the developing somatotropic axis should not be pharmacologically amplified with exogenous secretagogues.

What We Do Not Know: The Honest Evidence Gaps

The stack is mechanistically coherent but clinically unproven. The specific gaps are:

1. No human trial has tested TB-500 in any indication.
2. No study has examined the combination of Tβ4 (or its analogues) with any GHRH analogue.
3. The published CJC-1295 trials measure PK and GH/IGF-1 levels, not functional outcomes like healing time, strength, or injury recurrence.
4. Optimal dosing, cycling duration, and washout for the combination are entirely empirical.
5. Long-term safety data for either compound in humans are absent.

These are not minor gaps. A practitioner offering this stack has an obligation to present the evidence grade honestly to the patient. The phrase used in the Endocrine Society's 2019 clinical practice guideline on GH use captures the standard well: "The Endocrine Society does not recommend GH treatment for otherwise healthy adults with normal GH secretion." [15] CJC-1295 amplifies endogenous secretion rather than administering exogenous GH, but the downstream IGF-1 effect is directionally similar.